It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. We are initially focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies.
We are developing therapies to treat patients affected by diseases involving low pyrophosphate, or PPi, and adenosine, beginning initially with rare genetic diseases of ENPP1 deficiency and ABCC6 deficiency. The spectrum of manifestations of ENPP1 deficiency includes an infantile phase, a pediatric phase and an adult phase, formerly described as Generalized arterial calcification of infancy (GACI)/Autosomal-recessive hypophosphatemic rickets type 2 (ARHR2).
ABCC6 deficiency can lead to a vascular calcification condition resembling the acute infantile form of ENPP1 deficiency in infants and pseudoxanthoma elasticum (PXE) in older patients.
Our lead product candidate, INZ-701, is designed to replace the lost enzymatic function of genetically deficient ENPP1 by restoring the normal balance in PPi and adenosine for ENPP1 deficiency and providing therapeutic effect to treat other diseases, like ABCC6 deficiency, involving low PPi levels.
We believe people living with mineralization disorders deserve effective therapies. That’s why we’re working with scientists, physicians, and patients to develop breakthrough treatments for patients affected by debilitating diseases of abnormal mineralization.
Learn MoreAt Inozyme, we are always looking for talented individuals to join our team! If you thrive in an entrepreneurial environment where you can make a real difference in people’s lives, we encourage you to review our open positions.
Learn MoreYou are now signing up to receive email updates and news from Inozyme Pharma. The emails you will receive are not intended to provide you with healthcare advice. Inozyme Pharma will not and does not provide healthcare advice. By registering for this email service, you understand that you are not disclosing any personal, private health information to Inozyme Pharma.
You must be 18 years of age or older to register. By registering to receive these emails, you certify that you are 18 years of age or older and are granting permission to receive general updates and news from Inozyme Pharma.
By providing your information, you agree to allow Inozyme Pharma and its agents to collect the name and email address provided and to be contacted by Inozyme Pharma and its agents using this information in the future. Furthermore, you are agreeing that Inozyme Pharma and its agents may contact you by email. Inozyme Pharma will not sell, rent, or otherwise distribute your name and email address provided.
This site uses cookies as described in our Cookies Policy. To learn more about cookies, including how to disable them, view our Cookies Policy. By clicking the "Accept" or “Close” on this banner, or using our site, you consent to the use of Cookies, unless you disable them.
Accept